Radiomics predicts response of individual HER2‐amplified colorectal cancer liver metastases in patients treated with HER2‐targeted therapy
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Cancer"
DOI: 10.1002/ijc.33271
Abstract: The aim of our study was to develop and validate a machine learning algorithm to predict response of individual HER2‐amplified colorectal cancer liver metastases (lmCRC) undergoing dual HER2‐targeted therapy. Twenty‐four radiomics features were extracted after… read more here.
Keywords: response individual; response; individual her2; cancer ... See more keywords
Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.1c00710
Abstract: Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved irreversible HER2 inhibitors, neratinib and pyrotinib, both lack HER2 selectivity,… read more here.
Keywords: her2 amplified; sph5030; her2; tyrosine kinase ... See more keywords
Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas
Sign Up to like & getrecommendations! Published in 2021 at "Modern Pathology"
DOI: 10.1038/s41379-021-00997-2
Abstract: HER2 is an established therapeutic biomarker in advanced or recurrent endometrial serous carcinoma. Current clinical guidelines recommend HER2 testing exclusively in this endometrial carcinoma (EC) subtype; however, the full spectrum of ECs harboring HER2 amplification… read more here.
Keywords: ecs; high grade; amplification; her2 ... See more keywords
RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-62096-x
Abstract: HER2 amplification-associated molecular alterations and clinicopathologic features in colorectal cancers (CRCs) have not been well established. In this study, we assessed the prevalence of HER2 amplification and microsatellite instability (MSI) status of 992 patients with… read more here.
Keywords: her2 amplification; crcs; status; amplification ... See more keywords
Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy
Sign Up to like & getrecommendations! Published in 2018 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.1717820115
Abstract: Significance In HER2-amplified breast cancers, HER2 inhibitors have been very successful as adjuvant therapy but not as monotherapy. Here, we demonstrate that coamplification of a HER2 intronic miRNA causes intrinsic resistance to HER2 inhibitors by… read more here.
Keywords: breast; breast cancers; cancer; her2 ... See more keywords
Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects
Sign Up to like & getrecommendations! Published in 2025 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2025.2472411
Abstract: ABSTRACT Introduction Over the past 20 years, the treatment landscape of HER2-amplified tumors has considerably evolved. Until now, no approved targeted therapies were available for patients with HER2-amplified metastatic colorectal cancer (mCRC). Tucatinib, a highly selective… read more here.
Keywords: treatment; tucatinib treatment; her2; treatment her2 ... See more keywords
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
Sign Up to like & getrecommendations! Published in 2024 at "Future Oncology"
DOI: 10.1080/14796694.2024.2368952
Abstract: Summary What is this summary about? Researchers wanted to study whether the research drug zanidatamab could help people with a type of cancer called biliary tract cancer. In some people, biliary tract cancer cells make… read more here.
Keywords: cancer; zanidatamab; language; her2 amplified ... See more keywords
Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000023053
Abstract: Abstract The human epidermal growth factor receptor 2 (HER2) is amplified in approximately 20% of breast cancers, and HER2 receptor targeting therapy is associated with a significant improvement in disease-free and overall survival. In several… read more here.
Keywords: trastuzumab pertuzumab; therapy; her2; her2 amplified ... See more keywords
PO-519 Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified colorectal cancer models
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.1020
Abstract: Introduction Cetuximab and panitumumab, antibodies directed against the epidermal growth factor receptor (EGFR), are an effective clinical therapy for patients with metastatic colorectal cancer (mCRC), particularly for those with KRAS, NRAS, BRAF and PI3KCA wild-type… read more here.
Keywords: antitumor activity; anti egfr; cancer; her2 ... See more keywords
Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-b003
Abstract: Activation of HER2 signaling by amplification or overexpression of ERBB2 (HER2) is associated with the development and progression of breast cancer. Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor which selectively inhibits EGFR, HER2 and… read more here.
Keywords: combinatorial therapies; cancer; her2 amplified; neratinib her2 ... See more keywords
Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm
Sign Up to like & getrecommendations! Published in 2022 at "JCO Clinical Cancer Informatics"
DOI: 10.1200/cci.22.00022
Abstract: PURPOSE We compared overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)–amplified, treatment-refractory metastatic colorectal cancer (mCRC) receiving pertuzumab plus trastuzumab (PER-HER) in the phase IIa MyPathway multibasket study (ClinicalTrials.gov identifier:… read more here.
Keywords: external control; her2 amplified; arm; treatment refractory ... See more keywords